About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

By: via Business Wire

First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit

Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need. The discovery is the first using Logica®, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimized preclinical assets.

“Identification of this first lead candidate provides proof-of-concept for Logica as an engine to expedite and enhance drug discovery in a critical therapeutic area,” said Professor Julie Frearson, PhD, Senior Vice President and Chief Scientific Officer, Charles River. “Together with our partners at Valo Health and through our ongoing collaboration with Flagship’s Pioneering Medicines, we look forward to further leveraging the power of Logica to advance this program into lead optimization.”

Logica, the result of a strategic partnership between Charles River and Valo Health, is the industry’s first computation-powered, unified target-to-candidate offering. Logica leverages the integration of Valo Health’s AI-powered Opal Computational Platform™ and Charles River’s leading expertise in drug discovery and preclinical development.

A single integrated offering, Logica transforms the process of drug discovery by seamlessly translating targets to candidate nomination under a partnering business model. The Logica Advanceable Lead (Logica-AL) program integrates Valo’s DNA-encoded libraries and Opal Computational Platform with Charles River’s expertise in high-throughput screening to produce potent advanceable leads. The Logica Candidate (Logica-C) platform uses those leads and trained predictive models to rapidly advance a clinical program to deliver a candidate that will ultimately be ready for IND-enabling studies.

“We entered our collaboration with Charles River and Valo with a shared goal of accelerating the drug discovery process, and of expediting the development of critically needed therapies for patients with limited or no treatment options,” said Luisa Salter-Cid, Ph.D., Chief Scientific Officer, Pioneering Medicines. “Logica’s early success in identifying a potential therapy for an autoimmune disease has built confidence in that shared goal, and we are excited to continue working with the team as our program progresses.”

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Charles River’s dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about Charles River’s unique portfolio and breadth of services, visit www.criver.com.

About Valo Health

Valo Health, Inc is leveraging artificial intelligence (AI) and advanced analytics to better learn from the patient experience to discover and develop better medicines at greater speed and scale. The company’s Opal Platform™ is a human-centric, AI-driven drug development engine that uses AI to identify and validate novel drug targets using real-world data and human models to rapidly discover and develop small molecule therapies against those targets with more predictable safety and efficacy. Founded by Flagship Pioneering and headquartered in Lexington, Mass., Valo also has offices in New York, N.Y. and Tel Aviv, Israel. To learn more, visit valo​health​.com.

About Flagship Pioneering and Pioneering Medicines

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

Pioneering Medicines, Flagship Pioneering’s in house drug development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship’s innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship's multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts which are then advanced jointly with Flagship’s bioplatform companies. Within Flagship’s Innovation Supply Chain partnerships, Pioneering Medicines works with external collaborators to apply its unique approach to partners’ R&D priorities. These partnerships are highly co-creative strategic alliances that accelerate therapeutic innovation by bringing together partners spanning the full spectrum of drug discovery, development, and production.

“Logica’s early success in identifying a potential therapy for an autoimmune disease has built confidence in that shared goal, and we are excited to continue working with the team as our program progresses.”

Contacts

More News

View More
Etsy Partners With OpenAI—What It Means for Investors Now
Via MarketBeat
Topics Artificial Intelligence
Tickers ETSY
3 Solid Consumer Brands Offering Stability in Volatile Markets
Via MarketBeat
Topics Economy
Tickers AOUT JAKK KO PG SN
Lamb Weston: Is the King of Spuds a Buy or a Dud for 2026?
Via MarketBeat
Tickers LW
Palantir Stock Eyes New Highs, Boosted by Boeing Partnership
Via MarketBeat
Topics Artificial Intelligence
Tickers BA BAC PLTR
Marvell Soars on +$6B in Buybacks—Can the Recovery Continue?
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN AVGO MRVL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.